|
 |
BUSULFEXThis page contains recent news articles, when available, and an overview of BUSULFEX but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: BUSULFEX (when available) Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Mechanism Of Action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. News Articles on Busulfan Otsuka Pharma acquires rights to IV Busulfex from PDL BioPharma for … - Dec 17, 2007 NEW YORK (Thomson Financial) - Otsuka Pharmaceutical Co. Monday said it will acquire from PDL BioPharma Inc. the rights to PDL's IV Busulfex oncology ... Forbes PDL BioPharma Sale Fails to Please - Feb 5, 2008 In December, PDL sold its Busulfex IV to Otsuka Pharmaceutical Co. for $200 million. Credit Suisse analyst Y. Katherine Xu wrote in a note to investors that ... TheStreet.com - TheStreet.com (subscription) PDL BioPharma says selling commercial assets - Aug 28, 2007 O) on Tuesday said it would sell its commercial assets, including its Cardene, Retavase and IV Busulfex products, to focus on the discovery and development ... Reuters Event Brief of PDL to Acquire ESP Pharma, Inc. - Part 1. - Jan 25, 2005 Also in the hospital setting, ESP's IV Busulfex is marketed as a preconditioning ... IV Busulfex is a patent-protected potent cytotoxic drug, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Third Point calls for PDL BioPharma chairman's resignation, sale of … - Aug 29, 2007 The company will sell its Cardene, Retavase and IV Busulfex products, as well as a development-stage cardiovascular product. ... Bizjournals.com … Co Ltd acquires PDL Biopharma Inc-IV Busulfex from PDL Biopharma... - Mar 10, 2008 US - Otsuka Pharmaceutical Co Ltd acquired the IV Busulfex assets of PDL Biopharma Inc, a biopharmaceutical company, for $### mil in cash. Pay-Per-View - deals - Alacra Store … PDL BioPharma Close Sale of IV Busulfex. - PR Newswire | HighBeam ... - Mar 10, 2008 Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Protein Design Labs Becomes PDL BioPharma. - Jan 9, 2006 PDL BioPharma, the PDL BioPharma logo, Retavase and Busulfex are considered trademarks of PDL BioPharma, Inc. Cardene is a registered trademark of ... Free with registration - PR Newswire - AccessMyLibrary.com … Pharmaceutical Acquires Rights to IV Busulfex from PDL BioPharma. ... - Dec 17, 2007 Otsuka Pharmaceutical Acquires Rights to IV Busulfex from PDL BioPharma. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research PDL stops sale, will cut 260 people - Mar 5, 2008 Otsuka Pharmaceutical Co. of Japan will buy IV Busulfex for $200 million cash, ... Under PDL's management, Cardene, Retavase and Busulfex brought in $146.9 ... Bizjournals.com Event Brief of Q4 and Year-End 2006 PDL BioPharma Earnings … - Feb 21, 2007 IV Busulfex: 1. For the full-year and 4Q06 net sales of IVB Sulfax, a continuing agent ... IV Busulfex net sales growth continues to be largely driven by ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL Looks for a Push - Aug 2, 2006 For PDL to impress investors, it will have to be through its own drugs, such as Cardene, Retavase and Busulfex. Sales of Busulfex, which readies patients ... TheStreet.com - TheStreet.com (subscription) 大塚製薬ã€?ç±³PDL社ã?‹ã‚‰è¡€æ¶²ã?Œã‚“薬事æ¥ã‚’è²·å?Ž - Dec 19, 2007 ...大塚製薬ã?®æ¨‹å?£ç¤¾é•·ã?¯ã€ŒIV Busulfexã?®äº‹æ¥ç¶™æ‰¿ã€?ã?¨PDL社ã?ŒåŸ¹ã?£ã?¦ã??ã?Ÿã?Œã‚“é ˜åŸŸã?«ã?Šã?‘ã‚‹ 経験ã?¯ã€?大塚ã?®ã?Œã‚“é ˜åŸŸã?«ã?Šã?‘ã‚‹ã‚°ãƒãƒ¼ãƒ?ãƒ«å±•é–‹ã‚’åŠ é€Ÿã?•ã?›ã?¦ã?„ã??ã€?ã?¨è¿°ã?¹ã?¦ã?„る。 IBTimes … transplant drug Japanese company pays $200 million for Busulfex | ... - Dec 19, 2007 The deal involves Busulfex, which the U.S. Food and Drug Administration ... In addition to Busulfex, PDL markets Cardene for treating hypertension and ... Pay-Per-View - Oakland Tribune - HighBeam Research PDL BioPharma at Merrill Lynch Global Pharmaceutical, Biotech & … - Sep 22, 2006 Busulfex, on the other hand, has grown very nicely, has achieved very high percentage share of roughly 80% share in the basically conditioning regimen area. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com 오쯔카, ë°±í˜ˆë³‘ì¹˜ë£Œì œ IV Busulfex íŒ?권 ì?¸ìˆ˜ í•©ì?˜ - Dec 21, 2007 ...김윤ì˜? 기ìž?. ì?¼ë³¸ 오쯔카 ì œì•½íšŒì‚¬ëŠ” ë¯¸êµ PDLë°”ì?´ì˜¤íŒŒë§ˆì‚¬ì?˜ 백혈병 ì¹˜ë£Œì œ IV Busulfexì?˜ ìƒ?í‘œ, 특허, 지ì ?재산권 ë°? ê´€ë ¨ ìž?ì‚°ì—? 대해 현찰로 2ì–µ 달러를 ì§€ë¶ˆí•˜ê³ ... 메디í?¬ë‰´ìŠ¤ PDL BioPharma Announces Fourth Quarter and Full Year 2005 Financial … - Feb 27, 2006 Net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the quarter ... Of this, net sales of Cardene IV, Retavase and IV Busulfex for the year ... $4.95 - PR Newswire - ECNext TROUBLED PDL SELLS ONE OF ITS 3 DRUGS - LEUKEMIA … - Dec 18, 2007 The deal involves Busulfex, which the US Food and Drug Administration ... In addition to Busulfex, PDL markets Cardene for treating hypertension and ... $2.95 - San Jose Mercury News - NewsBank Protein Design to acquire ESP Pharma. - Jan 1, 2005 In the hospital setting, ESP's IV Busulfex is marketed as a preconditioning ... IV Busulfex is used in combination with cyclophosphamide as a conditioning ... Free with registration - BIOTECH Patent News - AccessMyLibrary.com Event Brief of Q3 2005 Protein Design Earnings Conference Call - Part... - Nov 1, 2005 IV Busulfex, a conditioning agent used in connection with bone marrow ... Net product sales for Cardene, Retavase, and Busulfex as a group totaled approx. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Mergers & Acquisitions; Medical laboratory acquires pharmaceutical … - Feb 21, 2005 In the hospital setting, ESP's IV Busulfex is marketed as a preconditioning ... IV Busulfex is used in combination with cyclophosphamide as a conditioning ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Otsuka closes buy of PDL products. - Mar 17, 2008 IV Busulfex is an oncologic product marketed and sold in the USA and Canada, and through distributors in a number of other countries. ... $9.94 - Pharma Marketletter - Alacra Store PDL BioPharma Announces Second Quarter 2007 Financial Results. - Aug 1, 2007 In July, a new vial formulation of the IV Busulfex product was launched in the ... Additionally, PDL has supported the expansion of IV Busulfex into new ... $4.95 - PR Newswire - ECNext PDL BioPharma Announces Third Quarter 2006 Financial Results. - Nov 2, 2006 IV Busulfex net sales were $5.2 million in the third quarter of 2006, compared to $5.4 million for the same period in 2005. * Royalty revenues for the third ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of Q2 2007 PDL BioPharma Earnings Conference Call - Final. - Aug 1, 2007 IV Busulfex, conditioning agent used in bone marrow ... Further, this week launched a new vial formulation of IV Busulfex initially in US, designed for ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL BioPharma Announces Second Quarter 2006 Financial Results. - Aug 3, 2006 IV Busulfex sales were $6.6 million in the second quarter of 2006, a 12 percent increase from $5.9 million for the same period in 2005. ... Free with registration - PR Newswire - AccessMyLibrary.com PDL Announces Third Quarter 2005 Financial Results. - Nov 1, 2005 Of this, net sales of Cardene(R) IV, Retavase(R) and IV Busulfex(R) for the quarter totaled approximately $38.0 million, while net sales of the four ... Free with registration - PR Newswire - AccessMyLibrary.com PDL's Buyout Of ESP Pharma: $475M For Drugs, Sales Team - Jan 26, 2005 The company also sells intravenous Busulfex for use in combination with ... Also patent protected, cytotoxic Busulfex is a formulation of the alkylating ... BioWorld Online - BioWorld Online Q2 2006 PDL BioPharma Earnings Conference Call - Part 1. - Aug 3, 2006 Sales of our third marketed product, Busulfex, a conditioning agent used in bone marrow transplantation were $6.6 million during the second quarter of 2006 ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q2 2005 Protein Design Earnings Conference Call -... - Aug 4, 2005 Busulfex. 1. At the same time, PDLI is pleased with the very high level of retention ... IV Busulfex, a condition agent used in connection with bone marrow ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Otsuka Pharmaceutical Co., Ltd. - Company Snapshot - AlacraStore.com - Oct 8, 2008 Otsuka Pharmaceutical Co Ltd acquires PDL Biopharma Inc-IV Busulfex from PDL ... US - Otsuka Pharmaceutical Co Ltd acquired the IV Busulfex assets of PDL ... Pay-Per-View - co - Alacra Store Q1 2006 PDL BioPharma Earnings Conference Call - Part 1. - May 2, 2006 We increased sales of Cardene and Busulfex, as current NDC data for these products, ... But, we're pleased with the ongoing growth for Cardene and Busulfex, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Article: Protein Design to acquire ESP Pharma. - BIOTECH Patent News... - Jan 1, 2005 In the hospital setting, ESP's IV Busulfex is marketed as a preconditioning ... IV Busulfex is used in combination with cyclophosphamide as a conditioning ... Pay-Per-View - BIOTECH Patent News - HighBeam Research Press Release: PDL BioPharma Announces Second Quarter 2006 … - Aug 3, 2006 IV Busulfex sales were $6.6 million in the second quarter of 2006, a 12 percent increase from $5.9 million for the same period in 2005. ... Pay-Per-View - PR Newswire - HighBeam Research PDL BioPharma Sets Another Asset Sale - Feb 21, 2008 And in December, PDL sold its Busulfex IV product to Japan's Otsuka Pharmaceutical for $200 million. All three deals, including Thursday's Genmab deal, ... TheStreet.com - TheStreet.com (subscription) Press Release: PDL BioPharma Announces Third Quarter 2006 Financial … - Nov 2, 2006 ...*IV Busulfex net sales were $5.2 million in the third quarter of 2006, compared to $5.4 million for the same period in 2005. *Royalty revenues for the third ... Pay-Per-View - PR Newswire - HighBeam Research PDL BioPharma at JPMorgan 25th Annual Healthcare Conference - Final. - Jan 11, 2007 If you look at our Cardene and our Busulfex market share, they both grew ... IV Busulfex is our drug for CML as a conditioning regimen associated with bone ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL BioPharma at JPMorgan 25th Annual Healthcare Conference - Final. - Jan 1, 2007 If you look at our Cardene and our Busulfex market share, they both grew ... IV Busulfex is our drug for CML as a conditioning regimen associated with bone ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q1 2007 PDL BioPharma Earnings Conference Call - Final. - May 2, 2007 Our other two hospital-based commercial products, IV Busulfex and Retavase, ... Net sales of IV Busulfex, a conditioning agent used in bone marrow ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com PDL BioPharma shares continue sliding - Mar 10, 2008 The company on Monday closed one of those sales, its IV Busulfex, to Ostuka Pharmaceutical Co. for $200 million. The drug is a conditioning agent used as a ... Boston Globe PDL's Potent Pick-Me-Up - Feb 27, 2006 IV Busulfex is approved as a conditioning agent to be used in combination with cyclophosphamide prior to blood or marrow transplant in patients with chronic ... BusinessWeek Market Commentary on PDL BioPharma Inc. - Mar 28, 2007 ...and IV Busulfex, an intravenous formulation of busulfan, ... as well as sells its IV Busulfex product through distributors in Europe and Asia. ... $4.95 - M2 Presswire - ECNext Press Release: Market Commentary on PDL BioPharma Inc. - M2 … - Mar 28, 2007 ...and IV Busulfex, an intravenous formulation of busulfan, ... as well as sells its IV Busulfex product through distributors in Europe and Asia. ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: PDL BioPharma Announces Fourth Quarter and Full Year … - Feb 21, 2007 Results for the 2005 period included approximately nine months of sales since the company began marketing Cardene(R) I.V., Retavase and IV Busulfex(R) ... Pay-Per-View - PR Newswire - HighBeam Research Allogeneic blood SCT for children with Hurler's syndrome: results... - Oct 13, 2008 The children enrolled in the main protocol (8/12 patients) received a fully myeloablative preparative regimen consisting of intravenous BU (Busulfex, ... Nature.com A case of therapy-related acute myeloid leukemia associated with... - Jan 26, 2006 ...(BMT) from an HLA-identical brother, with a conditioning regimen of fludarabine (30 mg/kg/day for 5 days) and busulfex (3.2 mg/kg/day for 2 days). ... Nature.com Correo del pueblo - eluniversal.com - Aug 28, 2005 Necesitamos: Busulfex 60Mg Amp. (5 Frascos), Cefepime 1g Caja x 2 viales (30 Frascos), Ciclosporina 100mg/ml Sol. Bebible. (2 frascos), Ciclosporina 50mg/ ... El Universal - El Universal (Venezuela) PDL Cheap? Don't Bet On It. - Aug 29, 2007 As part of the restructuring plan, PDL will shed four commercial products, including Cardene, Retavase, IV Busulfex and an ularitide development-stage ... Forbes eluniversal.com - Noticias de Venezuela y del Mundo - Nov 18, 2008 Estos medicamentos son imprescindibles para poder iniciar el trasplante de médula ósea que requiero para salvar mi vida: Busulfex 60mg/amp (16 ampollas), ... El Universal - El Universal (Venezuela) Vion Gets SPA Go-Ahead For AML Drug's Phase III - Feb 11, 2005 That drug is ESP's approved Busulfex, a formulation of busulfan for a different type of leukemia - chronic myelogenous - to be used in combination with ... BioWorld Online - BioWorld Online Third party mesenchymal stromal cell infusions fail to induce tissue... - Nov 1, 2007 Conditioning consisted of intravenous Busulfex 120 mg m - 2 daily with targeted drug dosing (day - 9 to - 6), cyclophosphamide 60 mg kg - 1 daily (day - 5 ... Nature.com Otsuka Buys Rights to PDL's Blood Cancer Drug for $200 Million - Dec 18, 2007 IV Busulfex is used to treat leukemia and is sold in more than 40 countries, the companies said. Otsuka will also seek to develop the drug for wider use in ... Bloomberg Genmab slakes capacity thirst with PDL facility purchase - Feb 25, 2008 Last December, PDL sold Japan's Otsuka Pharmaceutical the rights to IV Busulfex (busalfan), an oncology product used for conditioning prior to allogeneic ... OutSourcing-Pharma.com Q2 2005 Protein Design Earnings Conference Call - Final. - Aug 4, 2005 ...terrific new sales reps to our hospital-focused sales and marketing team to help fuel additional sales growth of Cardene IV, Retavase and IV Busulfex. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Protein Design Labs Announces Above Consensus Full-Year and Fourth … - Mar 14, 2005 Product revenues for Cardene IV, Retavase and IV Busulfex are expected to total approximately $93 to $95 million for the anticipated. Free with registration - PR Newswire - AccessMyLibrary.com Activist Dreams Come True at PDL BioPharma - Apr 11, 2008 Just a month later, PDL announced the $200 million sale of its IV Busulfex transplant drug to Japan's Otsuka Pharmaceuticals. Now, just a few months later, ... Investerms.com PDL BioPharma Announces Third Quarter 2007 Financial Results. - Nov 8, 2007 2007 2006 % Change Cardene(R) $37.0 $28.7 29 % IV Busulfex(R) 7.0 5.2 35 % Retavase(R) 4.9 7.2 -32 % Total marketed products $48.8 $41.1 19 % -- Royalty ... Free with registration - PR Newswire - AccessMyLibrary.com NETSUITE IPO TO PUT ELLISON EVEN FURTHER ABOVE THE … - Dec 17, 2007 The deal involves Busulfex, which the US Food and Drug Administration approved in 1999 to help prepare patients to receive bone marrow transplants to treat ... $2.95 - San Jose Mercury News - NewsBank Drug maker PDL to refocus goals, lay off 250 people: FREMONT FIRM TO … - Aug 29, 2007 1992 for hypertension; Retavase, which the FDA approved in 1996 for treating heart-attack victims; and Busulfex, approved in 1999 for treating leukemia. ... Pay-Per-View - San Jose Mercury News - HighBeam Research Q3 2006 PDL BioPharma Earnings Conference Call - Final. - Nov 2, 2006 PDL recognized net product sales of 41.1 million in the third quarter from sales of Cardene, Retavase, and IV Busulfex. Net product sales during the third ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Home administration of high-dose oral busulfan in patients undergoing... - Feb 26, 2007 Comparing average wholesale prices, iv Busulfex is roughly five times more expensive then oral BU. As both methods are currently used along with ... Nature.com Dr. Joy L. Frestedt Named Vice President of Clinical Affairs for … - Dec 13, 2005 Medical Information Scientist for Astra Zeneca Pharmaceuticals; and Manager of Busulfex Clinical Development for Orphan Medical in Minnetonka, ... RedOrbit PDL BioPharma to sell drug rights | Article from Oakland Tribune | … - Feb 6, 2008 In December, PDL sold its only other FDA-approved drug, Busulfex - - used to help prepare cancer patients to receive bone marrow transplants -- to Otsuka ... Pay-Per-View - Oakland Tribune - HighBeam Research Arup Will Develop Antibody-Based Busulfan Blood Monitoring Test - Oct 30, 2006 Arup Laboratories will develop a specialized test for measuring serum concentrations of the cancer chemotherapeutic agent busulfan (Busulfex®, ... Genetic Engineering News - Genetic Engineering News (press release) PDL BioPharma Announces First Quarter 2007 Financial Results. - May 2, 2007 2007 2006 % Change Cardene $34.5 $24.8 40% IV Busulfex(R) 7.7 5.2 49% Retavase(R) 6.9 6.5 6% Total marketed products 49.1 36.4 35% Off-patent products* ... $4.95 - PR Newswire - ECNext Autologous SCT with a dose-reduced BU and CY regimen in older … - Sep 15, 2008 Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell ... Nature.com Research & Markets: New Report Examines the Historical and … - Dec 28, 2006 Busulfex Cardiovascular Lercanidipine + enalapril Fractal 113 Diafusor Lercan Urology Permixon Womens health Optruma Testopatch ... Free with registration - Business Wire - AccessMyLibrary.com Emergency Nurses Association Names PDL Biopharma(R) as a 2007 … - Jun 13, 2007 ...and IV Busulfex(R) (http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning http://www.pdlbiopharma.com/index.cfm?navid=142) for conditioning ... Free with registration - PR Newswire - AccessMyLibrary.com Third Point Urges PDL BioPharma to Cut Costs. - Mar 5, 2007 ...you made what we consider to be an ill- conceived purchase of ESP Pharma for $500M to gain access to products Cardene IV, Retavase and Busulfex. ... Free with registration - PR Newswire - AccessMyLibrary.com PDL BioPharma at Cowen and Company Annual Health Care … - Mar 15, 2007 In 2006, we believe the made considerable progress against those objectives, growing both Cardene and IV Busulfex; achieving one or two market share with ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of PDL BioPharma Strategic Update - Final. - Aug 28, 2007 IV Busulfex. 4. Ularitide cardiovascular development program. 8. Engaged Merrill Lynch to conduct the sale process in Co.'s behalf and hopes to consummate ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Future forecasts for the key drugs sold by Pierre Fabre in the... - Apr 12, 2006 ...driven by Javlor and Busulfex, will propel the companys overall growth performanceEvaluate the strategies available to Pierre Fabre to sustain growth, ... Free with registration - M2 Presswire - AccessMyLibrary.com PDL BioPharma swings into 2nd-qtr profit.(Financial report) - Aug 13, 2007 Overall, revenues increased 25% to $49.0 million, with PDL's second best selling product, the anticancer agent Busulfex (busulfan), contributing $7.6 ... Free with registration - Pharma Marketletter - AccessMyLibrary.com PDL BioPharma loss widens, trial fails endpoint. - Aug 3, 2006 ...used to reduce high blood pressure during or after surgery; heart treatment Retavase; and chemotherapeutic agent IV Busulfex -- rose to $39 million from ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q2 2006 PDL BioPharma Earnings Conference Call - Part 2. - Aug 3, 2006 ...about a third was related to Retavase, and the remember to both Busulfex and the off patent branded products that we've now divested. JOEL SENDEK: Okay. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Stocks of the Week - Jul 16, 2007 Its portfolio of approved drugs includes Cardene, for high blood pressure; Retavase, for treating heart attacks; and IV Busulfex, which is used in ... fool.com StreetInsider.com After-Hours Movers 08/28 - Aug 28, 2007 PDL BioPharma Inc. (Nasdaq: PDLI) 15.8% LOWER; Plans to sell its commercial assets, including its Cardene, Retavase and IV Busulfex products, as well as the ... StreetInsider.com - StreetInsider.com (subscription) StreetInsider.com Unusual 11 Mid-Day Movers 08/29/2007 - Aug 29, 2007 PDL BioPharma Inc. (Nasdaq: PDLI) 20.5% LOWER; Plans to sell its commercial assets, including its Cardene, Retavase and IV Busulfex products, as well as the ... StreetInsider.com - StreetInsider.com (subscription) ePT@PharmTech.com.(IN THE FIELD: MONTH IN REVIEW) - Oct 1, 2007 The company plans to sell the rights to "Cardene," "Retavase," "IV Busulfex" and ularitide, and related assets, in one or more transactions. ... Free with registration - Pharmaceutical Technology - AccessMyLibrary.com Press Release: PDL Announces Third Quarter 2005 Financial Results. - ... - Nov 1, 2005 We're seeing solid combined net sales growth of our three actively marketed, recently acquired products, with both Cardene(R) and IV Busulfex(R) ... Pay-Per-View - PR Newswire - HighBeam Research PDL BioPharma CEO Mark McDade to resign, company to restructure. - Oct 1, 2007 As a result of its new focus, PDL plans to sell its commercial assets, including its Cardene, Retavase, and IV Busulfex products, as well as the ularitide ... $9.94 - Biopharm International - Alacra Store Article: Antidepressants show promise for fibromyalgia: tolerability... - Oct 1, 2008 ...with Pierre Fabre Medicament, granting the French company exclusive rights to market and distribute Busulfex(R) (busulfan) Injection in 21 European ... ... Pay-Per-View - Family Practice News - HighBeam Research FDA panel finds Chiron's cyclosporine inhalation solution safe, but... - Jun 10, 2005 ...and Drug Administration (FDA) Oncology Drugs Advisory Committee has recommended unanimously that Busulfex (busflfan) injection be approved to prepare . ... Pay-Per-View - Transplant News - HighBeam Research Investor Group acquires ORC Image et Strategies d through a leveraged... - Oct 20, 2008 Busulfex Injection (busulfan) Transplantation D ESP Pharma, Inc. , Jazz Pharmaceuticals…p- amino benzoate) Cancer Pain D -- ## Sucraid (sacrosidase) Sucrase ... Pay-Per-View - deals - Alacra Store Press Release: ARUP Laboratories and Saladax Biomedical Sign … - Oct 30, 2006 ...enable ARUP to develop a specialized test for measuring serum concentrations of the cancer chemotherapeutic agent busulfan (Busulfex(R), Myleran(R)). ... Pay-Per-View - PR Newswire - HighBeam Research Research and Markets: Future Forecasts for the Key Drugs sold by... - Apr 13, 2006 Learn how Pierre Fabres oncology franchise, driven by Javlor and Busulfex, will propel the companys overall growth performance ... $4.95 - Business Wire - ECNext Press Release: Emergency Nurses Association Names PDL Biopharma( … - Jun 13, 2007 ...and IV Busulfex(R) (http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning http://www.pdlbiopharma.com/index.cfm?navid=142) for conditioning ... Pay-Per-View - PR Newswire - HighBeam Research Future forecasts for the key drugs sold by Pierre Fabre in the... - Apr 12, 2006 ...driven by Javlor and Busulfex, will propel the companys overall growth performanceEvaluate the strategies available to Pierre Fabre to sustain growth, ... $4.95 - M2 Presswire - ECNext Press Release: Piper Jaffray Companies Announces 2004 Fourth Quarter … - Jan 26, 2005 ...quarter and year end results ... in part to increased fourth quarter sales of Busulfex ... the U.S. Bancorp Piper Jaffray Health Care Conference ... ... Pay-Per-View - PR Newswire - HighBeam Research Protein Design Labs Inc acquires ESP Pharma Inc - Deal Snapshot - … - Mar 24, 2005 Retavase or Busulfex? Mark McDade - Protein Design Labs Inc. - CEO Good questions, Matt…program, but Steve? Steven Benner - Protein Design Labs Inc. - Chief ... Pay-Per-View - deals - Alacra Store Protein Design Labs Announces First Quarter 2005 Financial Results. - May 2, 2005 ...feasible or desirable; IV Busulfex(R), a conditioning agent used in connection with bone marrow transplants; and four off-patent branded products. ... $4.95 - PR Newswire - ECNext Genmab buys PDL facility for $240M. - Mar 3, 2008 ...such as the $200.0 million from Japan's Otsuka for for Busulfex (busulfan) and $170.0 million from EKR Therapeutics for the rights to its cardiovascular ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Protein Design Labs Becomes PDL BioPharma. - PR … - Jan 9, 2006 ...and IV Busulfex(R) (busulfan), a pre-conditioning agent used in connection with bone marrow transplantation in chronic myelogenous leukemia. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: PDL BioPharma Announces Significant Strategic and … - Aug 28, 2007 ...commercial assets, including its Cardene(R), Retavase(R) and IV Busulfex(R) products, as well as the ularitide development-stage cardiovascular product. ... Pay-Per-View - PR Newswire - HighBeam Research PDL's 3rd-qtr loss falls 9% despite charges. - Nov 26, 2007 Additionally, revenues from IV Busulfex (busulfan), a cardiovascular disease treatment, increased 35% to $7.0 million. PDL's share price fell $0.11 to close ... $9.94 - Pharma Marketletter - Alacra Store PDL to sell commercial assets.(News Focus) - Nov 1, 2007 PDL's currently marketed products--Cardene (nicardipine HCI), Retavase (reteplase) and IV Busulfex (busulfan)--and the cardiovascular drug candidate ... $4.95 - Pharmaceutical Representative - ECNext Orphan Europe SARL acquires Jazz Pharm-Cystadane Rights from Jazz … - Mar 7, 2007 Medicinal Products (COMP) has recommended Orphan Designation in Europe for Xyrem oral solution for…announced that it acquired worldwide rights to Busulfex ... Pay-Per-View - deals - Alacra Store Research & Markets: New Report Examines the Historical and Forecast … - Dec 28, 2006 Busulfex Cardiovascular Lercanidipine + enalapril Fractal 113 Diafusor Lercan Urology Permixon Womens health Optruma Testopatch ... $4.95 - Business Wire - ECNext PDL BIOPHARMA INC - Jun 19, 2006 ...tavase to treat heart attacks and congestive heart failure, and Busulfex for use prior to stem cell trans-. plantation in chronic myelogenous leukemia. ... $35.00 - Stock Reports - Standard & Poor's Press Release: Third Point Urges PDL BioPharma to Cut Costs. - PR … - Mar 5, 2007 ...you made what we consider to be an ill- conceived purchase of ESP Pharma for $500M to gain access to products Cardene IV, Retavase and Busulfex. ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: BUSULFEX is also known by the following brand names and/or synonyms2041 C. B.; AN 33501; Busulfan; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; C.B. 2041; CB 2041; Citosulfan; G.T. 41; GT 2041; GT 41; Leucosulfan; Mablin; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum, Busulphan; Mylecytan; Myleran; Myleran Tablets; NCI-C01592; NSC 750; NSC-750; Nsc-750sulphabutin; Sulfabutin; Sulphabutin; Tetramethylene Dimethane Sulfonate; Tetramethylenester Kyseliny Methansulfonove; X 149 Drug Category: BUSULFEX is categorized under the following by the FDA: Antineoplastic Agents; Immunosuppressive Agents; Alkylating Agents; ATC:L01AB01 Dosage Forms: SOLUTION; TABLET Absorption: Completely absorbed from the gastrointestinal tract. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1,4-bis(methylsulfonyloxy)butane |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |